These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 8679448)

  • 41. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
    Oort FA; Terhaar Sive Droste JS; Van Der Hulst RW; Van Heukelem HA; Loffeld RJ; Wesdorp IC; Van Wanrooij RL; De Baaij L; Mutsaers ER; van der Reijt S; Coupe VM; Berkhof J; Bouman AA; Meijer GA; Mulder CJ
    Aliment Pharmacol Ther; 2010 Feb; 31(3):432-9. PubMed ID: 19878150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
    van Rossum LG; van Rijn AF; Verbeek AL; van Oijen MG; Laheij RJ; Fockens P; Jansen JB; Adang EM; Dekker E
    Int J Cancer; 2011 Apr; 128(8):1908-17. PubMed ID: 20589677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
    Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
    Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
    Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
    Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests.
    van Rossum LG; van Rijn AF; van Munster IP; Jansen JB; Fockens P; Laheij RJ; Dekker E
    Neth J Med; 2009 May; 67(5):182-6. PubMed ID: 19581668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening.
    Berchi C; Guittet L; Bouvier V; Launoy G
    Int J Technol Assess Health Care; 2010 Jan; 26(1):48-53. PubMed ID: 20059780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.
    Levi Z; Birkenfeld S; Vilkin A; Bar-Chana M; Lifshitz I; Chared M; Maoz E; Niv Y
    Int J Cancer; 2011 May; 128(10):2415-24. PubMed ID: 20658527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.
    Chausserie S; Levillain R; Puvinel J; Ferrand O; Ruiz A; Raginel T; Lantieri O; Launoy G; Guittet L
    Int J Cancer; 2015 Apr; 136(8):1827-34. PubMed ID: 25195670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Screening for colorectal cancer: current status in Japan.
    Saito H
    Dis Colon Rectum; 2000 Oct; 43(10 Suppl):S78-84. PubMed ID: 11052482
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Br J Cancer; 2009 Apr; 100(8):1230-5. PubMed ID: 19337253
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening.
    Shapiro JA; Bobo JK; Church TR; Rex DK; Chovnick G; Thompson TD; Zauber AG; Lieberman D; Levin TR; Joseph DA; Nadel MR
    Am J Gastroenterol; 2017 Nov; 112(11):1728-1735. PubMed ID: 29016558
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for colon cancer: A test for occult blood.
    Khakimov N; Khasanova G; Ershova K; Gibadullina L; Vetkina T; Lobisheva G; Chumakova A
    Int J Risk Saf Med; 2015; 27 Suppl 1():S110-1. PubMed ID: 26639687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience.
    Zappa M; Castiglione G; Paci E; Grazzini G; Rubeca T; Turco P; Crocetti E; Ciatto S
    Int J Cancer; 2001 Apr; 92(1):151-4. PubMed ID: 11279619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.